Full text is available at the source.
Abstract
Semaglutide may reduce the risk of cardiovascular death (CVD) based on findings from randomized controlled trials (RCTs).
- Cardiovascular death is a leading cause of mortality worldwide.
- Semaglutide is associated with a reduction in major adverse cardiovascular events (MACE).
- The effect of semaglutide on CVD varies among different patient groups.
- A comprehensive evaluation of semaglutide's impact on CVD risk is warranted.
Simplified